DATAGUARD
5.6.2024 17:29:34 CEST | Business Wire | Press release
DataGuard, a leading Software-as-a-Service (SaaS) company for security and compliance, announced today that it has acquired DPOrganizer. This acquisition expands DataGuard’s footprint particularly in the Nordic region and the UK, and strengthens the company’s market position across its core geographies Europe and North America. DataGuard helps over 4,000 customers active in more than 50 countries build robust security and compliance management systems. Companies use DataGuard’s software platform to get certified and become compliant with frameworks (such as GDPR, CCPA, ISO 27001, NIS 2, or SOC 2) as well as manage their most important risks efficiently, thereby staying ahead of evolving business and regulatory needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605633259/en/
Security & Compliance Management Software (Photo: Business Wire)
DPOrganizer, a Stockholm-based privacy management solution for privacy professionals and in-house data protection and compliance teams, helps small and large customers in more than 20 countries build and run effective privacy programs, comply with regulation, and build trust with their customers and partners. DPOrganizer’s powerful software toolkit offers incidents and breach management, data subject request handling, data protection impact assessments, and more functionalities. Thanks to the advanced data mapping, analytics and data flow visualization capabilities, data protection officers and privacy professionals can ensure collection and retention of data in line with regulation and best practice, identifying patterns and anomalies, and preventing breaches or non-compliance.
"Today’s announcement is a major milestone on DataGuard’s growth journey. Integrating DPOrganizer’s capabilities will enhance our offering for customers. It helps us build a unique system-of-record for the security and compliance domain that lets companies go beyond certifications and tick-the-box exercises,” says Thomas Regier, co-founder and co-CEO at DataGuard. “This and our comprehensive risk-first approach give DataGuard an asymmetric advantage as we transition into the era of AI-piloted security and compliance programs. We will continue to integrate strategic tech partners natively into our software ecosystem – to further broaden our customer value proposition and expand our geographic footprint.”
“In the era of data and artificial intelligence, organisations are constantly exposed to an increasing number of cyber threats and are required to comply with a multitude of frameworks to continue their business operations. As we know from our customers, ‘the risk is real’, and we believe the best way to address this is to have an effective digital information security and compliance management system. Partnering with DPOrganizer helps us further this mission,” said Kivanc Semen, co-founder and co-CEO at DataGuard.
“DPOrganizer was built for and is loved by privacy and compliance professionals. By joining forces with DataGuard, we can add capabilities such as the AI copilot, asset management, risk and controls management, and numerous information security frameworks. We thereby enable customers to build the bridge between security and compliance, expert and non-expert, business and compliance people. I am beyond excited to start this joint journey and combine our deep domain expertise and technological capabilities. We will continue to give thousands of customers a best-in-class experience,” Egil Bergenlind, co-founder of DPOrganizer summarizes.
About DataGuard
DataGuard is a security and compliance software company trusted by more than 4,000 organisations across the globe. Customers use the platform to build up a scalable risk management and a strong security posture while getting certified fast and complying effortlessly with industry regulation and frameworks such as ISO 27001, TISAX®, NIS2, SOC2, GDPR, and the EU Whistleblower Directive. Our purpose-built software suite offers AI-powered workflow automation and seamless integration capabilities, reducing the time and money organisations spend to build a digital Information Security Management System (ISMS) and Compliance Management System (CMS). DataGuard empowers organisations active in 50+ countries to better understand, identify, and manage the risks that matter most to them – and to build up a robust security and compliance posture that allows them to stay ahead of their evolving business and regulatory needs.
About DPOrganizer
DPOrganizer is a market leading provider of privacy management software that helps privacy professionals in 20+ countries to build more effective and sustainable data protection programs. The company offers an intuitive and easy to use software supporting customers with data mapping, assessment automation, reporting and visualization, data protection trainings, data subject request and incident management.
TISAX® is a registered trademark of the ENX Association. DataGuard is not affiliated with the ENX Association.
We provide Software-as-a-Service and support for the assessment on TISAX® only.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605633259/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom